Invest with us
Jonathan Rigby
Tel: +1.510.589.3268

Our Team
  • For more information, please visit:
  • Strategic Partnerships & Marketing
  • Clinical Studies
  • Production Scale-Up
  • Product Development

  • SteadyMed Ltd. (NASDAQ:STDY) is a specialty pharmaceutical company focused on the development of drug products to treat orphan and high value diseases with unmet parenteral delivery needs. The company`s lead candidate is Trevyent, a development stage drug product that utilizes SteadyMed`s PatchPump technology to administer treprostinil, a vasodilatory prostacyclin analogue to treat pulmonary arterial hypertension. PatchPump is a proprietary, disposable, parenteral drug administration platform that is prefilled and preprogrammed at the site of manufacture. SteadyMed has offices in San Ramon, California and Rehovot, Israel.       


    - The market for Biologic drugs, drugs that need to be injected or infused, is continuously growing.

    - The current global Biologic drug market is valued at $120 billion.

    - Current injection technologies can deliver only small dosages and low viscosity drugs, thus addressing only half of the biologic drugs market potential.